This finding is consistent with several other analyses examining ACE inhibitor and/or ARB use as risk factors for worse COVID-19 outcomes, including at least one that suggests a protective effect against adverse COVID-19 outcomes [21–25, 68]. Here, ACE is linked to COVID-19.